C43 Stock Chart & Stats
€60.40
€2.60(3.80%)
At close: 4:00 PM EDT
€60.40
€2.60(3.80%)
Day’s Range― - ―
52-Week Range€52.90 - €141.00
Previous CloseN/A
Volume100.00
Average Volume (3M)25.00
Market Cap
€962.02M
Enterprise Value€963.95M
Total Cash (Recent Filing)€195.28M
Total Debt (Recent Filing)€4.33M
Price to Earnings (P/E)―
Beta1.00
Next Earnings
Mar 24, 2027EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.38
Shares Outstanding17,543,522
10 Day Avg. Volume22
30 Day Avg. Volume25
Financial Highlights & Ratios
PEG Ratio4.78
Price to Book (P/B)3.74
Price to Sales (P/S)17.21
P/FCF Ratio-113.83
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€124.21Price Target Upside105.64% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)0.15
Revenue Forecast (FY)€115.82M
Bulls Say, Bears Say
Bulls Say
Conservative Balance SheetVery low leverage and substantial equity provide financial resilience while operating performance is under pressure. This capital structure can preserve strategic flexibility, support continued product development, and reduce interest-related constraints during periods of weaker profitability or cash generation.
Diversified Pharmaceutical Revenue ModelCombining proprietary product sales with licensing, royalties, milestones, and potential supply revenue gives COSMO multiple routes to monetize its gastrointestinal and endoscopy capabilities. Partnerships can broaden commercial reach and create recurring or milestone-based income alongside direct sales.
Demonstrated Cash-generation CapacityAlthough cash generation weakened sharply in 2025, the strong 2024 operating and free cash flow results show that the business has previously converted activity into substantial internal funding. That demonstrated capacity could support reinvestment if product performance and earnings normalize.
Bears Say
Sharp Revenue ContractionThe large year-over-year revenue decline indicates that the current commercial run-rate is substantially weaker than the prior year. Such volatility makes planning and resource allocation harder, and it raises the risk that future investment and earnings depend on uneven product or partnership outcomes.
Negative Operating And Free Cash FlowA shift from strong positive cash generation to operating and free cash outflows weakens the quality and sustainability of current earnings. Continued cash burn could reduce internally funded investment capacity and make recovery dependent on renewed operating performance rather than existing business cash generation.
Inconsistent ProfitabilityRepeated swings between strong profits and losses show that COSMO has not yet established a consistently profitable operating base. Negative 2025 margins, following an unusually strong 2024, reduce earnings visibility and make it harder to assess the sustainable contribution of its products and partnerships.
COSMO Pharmaceuticals N.V. News
C43 FAQ
What was COSMO Pharmaceuticals N.V.’s price range in the past 12 months?
COSMO Pharmaceuticals N.V. lowest stock price was €52.90 and its highest was €141.00 in the past 12 months.
What is COSMO Pharmaceuticals N.V.’s market cap?
COSMO Pharmaceuticals N.V.’s market cap is €962.02M.
When is COSMO Pharmaceuticals N.V.’s upcoming earnings report date?
COSMO Pharmaceuticals N.V.’s upcoming earnings report date is Mar 24, 2027 which is in 151 days.
How were COSMO Pharmaceuticals N.V.’s earnings last quarter?
COSMO Pharmaceuticals N.V. released its earnings results on Jul 23, 2026. The company reported -€0.279 earnings per share for the quarter, missing the consensus estimate of €0 by -€0.279.
Is COSMO Pharmaceuticals N.V. overvalued?
According to Wall Street analysts COSMO Pharmaceuticals N.V.’s price is currently Undervalued.
Does COSMO Pharmaceuticals N.V. pay dividends?
COSMO Pharmaceuticals N.V. does not currently pay dividends.
What is COSMO Pharmaceuticals N.V.’s EPS estimate?
COSMO Pharmaceuticals N.V.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does COSMO Pharmaceuticals N.V. have?
COSMO Pharmaceuticals N.V. has 17,543,522 shares outstanding.
What happened to COSMO Pharmaceuticals N.V.’s price movement after its last earnings report?
COSMO Pharmaceuticals N.V. reported an EPS of -€0.279 in its last earnings report, missing expectations of €0. Following the earnings report the stock price went down -0.292%.
Which hedge fund is a major shareholder of COSMO Pharmaceuticals N.V.?
Currently, no hedge funds are holding shares in DE:C43
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
COSMO Pharmaceuticals N.V.
Cosmo NV engages in the development and manufacture of treatments and products for gastrointestinal diseases and dermatology. Its products include Lialda/Mezavant/Mesavancol, Uceris/Cortiment, Winlevi, GI Genius, Lumeblue, Aemcolo/Relafalk, Eleview, and Byfavo. The company was founded by Mauro Severino Ajani in 1997 and is headquartered in Dublin, Ireland.
C43 Stock 12 Month Forecast
Average Price Target
€124.21
▲(105.64% Upside)